Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 14.51% is 24% above its 5-year average of 11.67%, near the high end of its 5-year range (1.05%–19.22%).
As of the fiscal period ended Tuesday, June 30, 2026. 5.18% below its 12-month average of 15.30%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 14.51%.
DEBT TO ASSETS RATIO
14.51%
DEBT TO ASSETS RATIO AVG TTM
15.30%
DEBT TO ASSETS RATIO AVG 3Y
14.86%
DEBT TO ASSETS RATIO AVG 5Y
11.67%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-5.18%
CURRENT VS 3Y AVG
-2.36%
CURRENT VS 5Y AVG
+24.34%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+16018.64%
vs the sector median at left
Tarsus Pharmaceuticals, Inc.
Market Cap
$3.19B
Debt to Assets Ratio
14.51%
TTM Avg
15.30%
3Y Avg
14.86%
5Y Avg
11.67%
Market Cap
$3.12B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.31B
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.06B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.03B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.36B
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.38B
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.99B
Debt to Assets Ratio
0.23%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | $3.19B | 14.51% | 15.30% | 14.86% | 11.67% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | 0.02% | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.30B | 0.04% | N/A | N/A | N/A |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | 0.01% | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | 0.02% | N/A | N/A | N/A |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.03B | 0.00% | N/A | N/A | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | 0.04% | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 0.04% | N/A | N/A | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 0.23% | N/A | N/A | N/A |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | 0.06% | N/A | N/A | N/A |
Debt/Assets
14.5%
Debt/Equity
0.26
Current Ratio
3.20
Interest Coverage
-7.9x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 14.51% |
| 2026-03-31 | 15.26% |
| 2025-12-31 | 16.66% |
| 2025-09-30 | 15.43% |
| 2025-06-30 | 14.64% |
| 2025-03-31 | 14.45% |
| 2024-12-31 | 19.22% |
| 2024-09-30 | 19.22% |
| 2024-06-30 | 19.15% |
| 2024-03-31 | 8.74% |
| 2023-12-31 | 11.38% |
| 2023-09-30 | 11.23% |
| 2023-06-30 | 13.25% |
| 2023-03-31 | 11.94% |
| 2022-12-31 | 8.87% |
| 2022-09-30 | 8.50% |
| 2022-06-30 | 7.98% |
| 2022-03-31 | 11.25% |
| 2021-12-31 | 1.06% |
| 2021-09-30 | 1.22% |
| 2021-06-30 | 1.05% |
| 2021-03-31 | 0.35% |
| 2020-12-31 | 0.48% |
| 2020-09-30 | 0.88% |
| 2020-06-30 | 1.52% |
| 2019-12-31 | 0.28% |
